SANNV Stock Overview

A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More details

SANNV fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	3/6

Rewards

Trading at 57.2% below our estimate of its fair value

Earnings are forecast to grow 14.84% per year

Risk Analysis

Shares are highly illiquid

Dividend of 3.93% is not well covered by earnings or free cash flows

Large one-off items impacting financial results

Profit margins (9.3%) are lower than last year (19.8%)

My Notes

Capture your thoughts, links and company narrative

Sanofi Competitors

Ipsen

ENXTPA:IPN

€9.7b

Virbac

ENXTPA:VIRP

€2.7b

Vetoquinol

ENXTPA:VETO

€911.1m

Boiron

ENXTPA:BOI

€464.4m

Price History & Performance

Summary of share price highs, lows and changes for Sanofi
Historical stock prices
Current Share Price	€93.74
52 Week High	€0
52 Week Low	€0
Beta	0.44
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	SANNV	FR Pharmaceuticals	FR Market
7D	n/a	2.5%	1.2%
1Y	n/a	0.5%	0.1%

Return vs Industry: Insufficient data to determine how SANNV performed against the French Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how SANNV performed against the French Market.

Price Volatility

Is SANNV's price volatile compared to industry and market?
SANNV volatility
SANNV Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	3.7%
Market Average Movement	4.4%
10% most volatile stocks in FR Market	9.7%
10% least volatile stocks in FR Market	2.4%

Stable Share Price: SANNV's share price has been volatile over the past 3 months compared to the French market.

Volatility Over Time: Insufficient data to determine SANNV's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1994	86,088	Paul Hudson	www.sanofi.com

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Sanofi Fundamentals Summary

How do Sanofi's earnings and revenue compare to its market cap?
SANNV fundamental statistics
Market cap	€119.38b
Earnings (TTM)	€4.51b
Revenue (TTM)	€48.45b

26.5x

P/E Ratio

2.5x

P/S Ratio

Is SANNV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SANNV income statement (TTM)
Revenue	€48.45b
Cost of Revenue	€14.96b
Gross Profit	€33.48b
Other Expenses	€28.98b
Earnings	€4.51b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Jan 30, 2025

Earnings per share (EPS)	3.61
Gross Margin	69.12%
Net Profit Margin	9.30%
Debt/Equity Ratio	32.5%

How did SANNV perform over the long term?

See historical performance and comparison

Dividends

3.9%

Current Dividend Yield

112%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/08 01:38
End of Day Share Price	2025/01/08 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sanofi is covered by 62 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kamla Singh	AlphaValue
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research